Anti-Human OX40L (Oxelumab)

IVMB0211

Product Information

| Product SKU : | IVMB0211 | Clone: | R4930 | Target: | TNFSF4 | |
|----------------------|--------------------------------------|-------------|-----------------------|----------------------|-------------------|--|
| Size: | 1.0 mg, 100 mg, 25 mg, 5.0 mg, 50 mg | | | lsotype: | Human lgG1ĸ | |
| | | | | | | |
| Additional In | formation | | | | | |
| Reactivity: | Human | | | Host Species: | Human | |
| Antibody Type | : Biosimilar Recomb | inant Humar | n Monoclonal Antibody | Expression Ho | st: HEK-293 Cells | |
| | | | | | | |

Immunogen Information

| Background: | Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune |
|------------------------------------|--|
| | diseases. ³ Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor |
| | necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an |
| | optimal T cell response and plays a significant role in determining the amount of memory |
| | T-cells remaining after the immune response. ¹ Therapeutic treatments with antibodies |
| | against TNFSF can sometimes result in serious side effects. ² More research is needed to |
| | understand the precise molecular mechanism of TNF inhibition. This cost-effective, |
| | research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the |
| | therapeutic antibody Oxelumab making it ideal for research projects. |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| | |
| | |
| Applications: | В |
| | |
| Applications: Synonyms: | B TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B |
| | |
| Synonyms: | TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B |
| Synonyms: | TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular |
| Synonyms: Antigen Distribution: | TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells. |
| Synonyms: Antigen Distribution: | TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells. |





or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

- Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the
therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product
is for research use only.
- Product Preparation:
 Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
- Storage & Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to
one month. For longer term storage, aseptically aliquot in working volumes without diluting
and store at -80°C. Avoid Repeated Freeze Thaw Cycles.